EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion

Jinyao Liu iD, Yingying Pang, Wenyan Li, Juanjuan Sun, Yujie He, Yonghong Guo, Jing Dong iD

Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)

DOI: 10.1128/aac.01892-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Jinyao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Training Base at Shanghai Pudong New Area Gongli Hospital, Ningxia Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Linezolid, Renal Insufficiency, Liver, Anti-Bacterial Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission, Academic Leaders Training Program of Shanghai Pudong New Area Health Commission, Medical Discipline Construction Program of Shanghai Pudong New Area Health Commission (the Key Disciplines Program).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Linezolid, an oxazolidinone antibiotic, is used in patients with liver or kidney disease. However, the effects and mechanisms of hepatic impairment or renal failure on the pharmacokinetics of linezolid and its metabolites (PNU-142586 and PNU-142300) remain unclear. We used carbon tetrachloride-induced impaired hepatic function and 5/6 nephrectomy-induced renal failure rat models to investigate linezolid and metabolite pharmacokinetics. Isolated primary rat hepatocytes were used to evaluate the impact of hepatic impairment or renal failure on linezolid metabolism. Uptake and efflux transport studies were also conducted. The influence of hepatic impairment or renal failure on the pharmacokinetics of linezolid and two metabolites did not differ between intragastric gavage and intravenous administration in rats. Linezolid did not accumulate in the brain, heart, lung, liver, kidney, and small intestinal tissues of the hepatic impairment or renal failure rats. And PNU-142300 did not accumulate in the liver or kidney tissue. Compared to the isolated normal rat hepatocytes, the in vitro hepatic clearance of linezolid in hepatic impairment and renal failure rat hepatocytes decreased by 61.3% and 44.1%, respectively. Organic anion transporting polypeptide (OATP)1B1, OATP1B3, OATP2B1, Na+-taurocholate co-transporting polypeptide (NTCP), organic anion transporter (OAT)1, OAT3, multidrug resistance-associated protein 2 (MRP2), or multidrug resistance protein 1 (MDR) did not mediate linezolid transport. Hepatic impairment primarily increases linezolid exposure through reduced hepatic metabolism, whereas renal failure increases both linezolid and two metabolites exposure through reduced hepatic metabolism and renal glomerular filtration. These findings guide adjusting the dose of linezolid in patients with hepatic and renal insufficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidRenal InsufficiencyLiverAnti-Bacterial AgentsAnimalsRatsHepatocytesMaleRats, Sprague-DawleyKidneyCarbon TetrachlorideRenal Elimination

Stichwörter der Autor:innen

drug transporterhepatic impairmenthepatic metabolismlinezolidpharmacokineticsrenal failure

Substanzen

LinezolidAnti-Bacterial AgentsCarbon Tetrachloride

Autor:innen und Institutionen

  • Postgraduate Training Base at Shanghai Pudong New Area Gongli Hospital, Ningxia Medical University, Shanghai, China.
  • Department of Pharmacy, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
  • Department of Pathology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.

ORCID-Profile: Jinyao Liu, Jing Dong

Förderung

  • Shanghai Municipal Health Commission
  • Academic Leaders Training Program of Shanghai Pudong New Area Health Commission
  • Medical Discipline Construction Program of Shanghai Pudong New Area Health Commission (the Key Disciplines Program)

Zitieren

APA

Liu, J., Pang, Y., Li, W., Sun, J., He, Y., Guo, Y., & Dong, J. (2025). Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01892-24

Vancouver

Liu J, Pang Y, Li W, Sun J, He Y, Guo Y, et al. Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01892-24

BibTeX
@article{Liu2025,
  author = {Liu, Jinyao and Pang, Yingying and Li, Wenyan and Sun, Juanjuan and He, Yujie and Guo, Yonghong and Dong, Jing},
  title = {Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {5},
  doi = {10.1128/aac.01892-24}
}
Kostenlos starten →